CION Ameerpet
Precancer Explained · Reviewed by CION Oncologists · NABH Accredited
Atypical Endometrial Hyperplasia — A Precancer, Not a Cancer
If your biopsy report says atypical hyperplasia, or uses the newer term EIN, two things are true at once and you need both of them. This is not cancer. You have not been diagnosed with a malignancy, nothing is being staged, and no oncology treatment is starting today. And this is the type that is taken seriously — the one form of thickened lining where a hysterectomy is usually recommended rather than watched. Holding both facts together is uncomfortable, but it is the accurate position, and it is a far better one to be in than a cancer diagnosis.
- Not a cancer diagnosis — no stage, no grade, no oncology treatment on the strength of this report alone
- The cells look abnormal — that is what “atypia” means, and it is what separates this from the common type
- Real risk of progressing — roughly a quarter to a third of women over about two decades if left
- Surgery is usually advised — and it both treats the precancer and answers what is already there
17+
Cancer Specialists
on Panel
on Panel
35+
Centres
Across India
Across India
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
What “Atypia” Actually Describes
Every case of endometrial hyperplasia involves a lining that has overgrown. The pathologist then asks a second question, and it is the one that decides everything: do the individual cells look normal?
In hyperplasia without atypia, they do. The glands are crowded and the architecture is disordered, but each cell is an ordinary endometrial cell. In atypical hyperplasia they are not. The nuclei are enlarged, rounder, more irregular, with a changed internal appearance. The tissue has begun to acquire the features of a cancer without yet being one — which is the definition of a precancer.
- EIN and atypical hyperplasia mean the same thing in practice. EIN — endometrioid intraepithelial neoplasia — comes from a different classification system built around the same biology. If your report uses one term and this page uses the other, they are describing the same diagnosis.
- The older wording still appears. Reports sometimes read “complex hyperplasia with atypia” or “simple hyperplasia with atypia”, from the previous four-category system. What matters in all of them is the last two words.
- It is a judgement made under a microscope. Distinguishing atypia from a reactive change, and distinguishing atypia from an early carcinoma, are among the harder calls in gynaecological pathology. Where that call decides whether you keep your uterus, it is reasonable to ask for the slides to be reviewed.
For the other type, and for how the two are classified side by side, see endometrial hyperplasia and hyperplasia without atypia.
Did You Know? The strongest argument for removing the uterus in atypical hyperplasia is not what the precancer might become — it is what may already be there. An outpatient biopsy samples a small part of the lining, so it can find atypia in one area while missing a carcinoma in another. In a large prospective surgical study, women whose biopsy showed atypical hyperplasia were found to have an endometrial carcinoma in the removed uterus in around four cases in ten, and a proportion of those cancers had already invaded the muscle wall. The hysterectomy is therefore doing two jobs: it treats the precancer, and it settles a question the biopsy could not. Sources: Gynecologic Oncology Group prospective study of concurrent carcinoma in complex atypical hyperplasia (Trimble et al., Cancer); World Health Organization classification of tumours of female reproductive organs; RCOG / BSGE Green-top Guideline No. 67; NCCN Clinical Practice Guidelines in Oncology — Uterine Neoplasms.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
What This Diagnosis Changes — and What It Does Not
| The question | The answer |
|---|---|
| Do I have cancer? | No. Atypical hyperplasia is a precancerous change, not a carcinoma. It has no stage and no grade. If a cancer is later found in the removed uterus, that is a new and separate diagnosis — and it is usually found early. |
| Is it urgent? | It is not an emergency, but it should not drift. The reasonable timeframe is weeks, not months: a specialist appointment, a decision, and a plan. What is not reasonable is being told it is benign and given no follow-up. |
| Why is surgery recommended? | For two reasons that are often collapsed into one. It removes tissue that carries a real risk of becoming cancer, and it examines the whole lining so that a carcinoma already present is not missed. A biopsy samples; a hysterectomy answers. |
| Can I keep my uterus? | Yes, in defined circumstances — principally if you want to conceive, or if surgery carries too much risk for you. It means hormone treatment plus repeat biopsies at short intervals, and an agreement about what happens if it does not clear. See hyperplasia and fertility. |
| Will the ovaries be removed too? | That is a separate decision from removing the uterus, and it turns largely on whether you have been through the menopause. In younger women it is weighed against the consequences of surgical menopause. See removing the ovaries and tubes. |
| Is ablation an option instead? | No. Endometrial ablation destroys the lining rather than removing it for examination, leaves tissue behind that cannot be sampled afterwards, and is not an accepted treatment for atypical hyperplasia. If it has been offered to you, ask why. |
The one thing worth being firm about: a diagnosis of atypical hyperplasia should be discussed with a specialist who treats endometrial cancer, not managed as a general gynaecology problem. Not because it is a cancer — it is not — but because the decisions that follow it are the same decisions, and the chance of a carcinoma sitting alongside it is too high for the question to be left open.
Told You Have Atypia, and Not Sure What Happens Next?
Bring the biopsy report. Forty-five minutes is enough to explain the finding, the real risk, and every option including the ones that keep your uterus.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
This Is the Diagnosis Where Acting Early Genuinely Changes the Outcome
A precancer treated is a cancer that never happens. Very little in oncology offers that; this does.
The Two Routes, and Who Each One Is For
There is a standard recommendation and a recognised alternative. Which is right depends on your age, whether you want children, and what surgery would cost you in risk.
Standard
Total Hysterectomy
Removal of the uterus and cervix. It is definitive, it removes the risk of progression entirely, and it identifies a coexisting cancer if one is there. Usually laparoscopic or robotic. See what to expect.
Standard
The Ovary Decision
Taken separately. After the menopause, removal is usually advised. Before it, the benefit is weighed against surgical menopause and its long-term effects on bone and heart health.
Alternative
Fertility-Sparing Progestin Therapy
High-dose progestin, often via a hormone-releasing intrauterine device, for a woman who wants to conceive. Recognised in guidelines, not a compromise — but it depends on strict surveillance.
Alternative
Hormone Therapy When Surgery Is Unsafe
Where obesity, heart disease or other conditions make an operation genuinely hazardous, hormone treatment with repeat sampling is the accepted route rather than the second-best one.
Required either way
Surveillance Biopsies
If the uterus stays, repeat sampling at short intervals is not optional — it is the mechanism by which a non-surgical plan is made safe. A plan without it is not a plan.
Required either way
Treating the Cause
Weight, blood sugar and hormone exposure produced this lining and will go on producing it. Addressing them is part of the treatment, not lifestyle advice attached to the end of it.
For women who want to conceive
Keeping Your Uterus: What the Fertility-Sparing Route Actually Requires
This is a legitimate, guideline-recognised path — and it asks a great deal of the woman who takes it. Every point below is a condition of doing it safely, not a formality.
A confirmed diagnosis of atypia with no evidence of cancer
Before anything else, the diagnosis has to be right. That means slides reviewed by a pathologist experienced in this area, and imaging — usually MRI — to look for any sign that a cancer is present and has invaded the muscle of the uterine wall. If there is invasion, or if the pathology is read as carcinoma rather than atypia, the fertility-sparing route closes. Hysteroscopic assessment is often used as well, so the cavity is seen directly rather than sampled blind.
A genuine, current wish to become pregnant
This route exists to preserve fertility, and it carries risk in exchange for that. It is not a way to avoid surgery in general. Guidelines are explicit that it is for women who want to conceive, and it usually comes with an agreement that the uterus will be removed once childbearing is complete — a conversation worth having at the start rather than years later. See completing treatment after childbearing.
High-dose progestin, delivered reliably
The treatment is progestin — the hormone class that opposes oestrogen — given at high dose. A hormone-releasing intrauterine device places it directly against the lining and avoids the problem of remembering tablets; oral treatment is used where a device is unsuitable. The choice is a clinical one, but the principle is the same in both: sustained, uninterrupted exposure of the lining to a progestin over months.
Repeat biopsies at short intervals, without exception
This is the part that makes the route safe, and the part women most often underestimate. Sampling is repeated every few months to confirm the atypia is regressing, and a first clear result is not the end of it — treatment and surveillance continue. If the lining has not responded within a defined window, the recommendation reverts to surgery. Missing these appointments removes the entire safety mechanism.
A plan for conception, made early
Regression is not the goal in itself; pregnancy is. Once the lining has cleared, the window before the atypia can return is finite, so referral to reproductive medicine is made early rather than after a long wait. Assisted reproduction is often involved, both because it shortens the time to conception and because many women in this situation have the anovulatory background that caused the hyperplasia. See IVF after treatment.
Honest acceptance of the recurrence risk
Even when it works, hormone treatment leaves the uterus in place and leaves the hormonal cause largely unaddressed, so a proportion of women see the atypia return — sometimes years later. That is not an argument against the route; it is the reason the follow-up continues long after the initial response, and the reason the completion hysterectomy is discussed openly. See recurrence risk with fertility-sparing treatment.
Atypical Hyperplasia on Your Report?
We will review the pathology, tell you what the risk actually is in your case, and go through every route including the ones that keep your uterus. The opinion is free.
If a Cancer Is Found in the Removed Uterus
It happens in a meaningful minority of cases, so it is worth knowing in advance rather than hearing for the first time in a results appointment. The pathologist examines the whole lining after surgery, and sometimes finds a carcinoma that the biopsy could not reach.
The important context: these cancers are overwhelmingly found early. They are usually confined to the uterus, most often low grade, and in many cases the hysterectomy that was performed for the precancer has already treated them completely. What changes is not the operation — that has happened — but the follow-up.
- Staging is completed on the specimen. How deeply the tumour went into the muscle wall, and whether it reached the cervix, are read from the tissue already removed. That produces a FIGO stage, most commonly stage 1.
- Mismatch repair status is tested. Every endometrial tumour is tested for MMR proteins and microsatellite instability. It informs treatment choice and flags who should be offered Lynch syndrome counselling. See MMR and MSI testing.
- The tumour board decides whether anything follows. Many early, low-grade tumours need no treatment after surgery at all. Others are offered a short course of vault brachytherapy to protect against local recurrence. See the adjuvant decision.
- Node assessment may have been done at the same operation. Where the risk profile warranted it, sentinel node mapping is performed during the hysterectomy, which is one reason the operation is best done somewhere equipped to do it. See sentinel node biopsy.
Why an EIN Report Is Worth a Specialist Opinion
The decisions that follow atypical hyperplasia are the same decisions that follow an early cancer. They deserve the same team.
Slides reviewed, not just the summary line
Named MCh surgical oncologists
Fertility taken seriously
Tumour board for every diagnosis
MMR / MSI testing as standard
Decisions for healing, not billing
Take The Next Step
A Precancer Is the Best News You Can Get in This Part of Medicine
It means there is still a decision to make, and time to make it well. Let us go through it with you.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
Atypical Endometrial Hyperplasia — Frequently Asked Questions
Is atypical endometrial hyperplasia cancer?
No. Atypical hyperplasia — also reported as EIN, or endometrioid intraepithelial neoplasia — is a precancerous change in the lining of the uterus. It has no stage and no grade, and it is not treated as a malignancy. What makes it different from ordinary hyperplasia is that the individual cells look abnormal under the microscope, which is what "atypia" means. That matters for two reasons: a substantial proportion of women progress to endometrial cancer over the following years if it is left, and in a significant minority of cases a cancer is already present elsewhere in the lining where the biopsy did not reach. Both are reasons for a plan, not reasons to panic.
Why is a hysterectomy recommended if it is not cancer?
Because it does two jobs at once. It removes tissue that carries a real risk of becoming cancer, which no amount of monitoring can do. And it allows the entire lining to be examined, which settles the question a biopsy cannot answer — whether a carcinoma is already present in a part of the uterus that was not sampled. In a large prospective surgical series, around four in ten women whose biopsy showed atypical hyperplasia turned out to have a cancer in the removed uterus, and those cancers were mostly early. Endometrial ablation is not an alternative, because it destroys the lining rather than removing it for examination.
Can I keep my uterus if I want children?
Yes, and this is a recognised route in international guidelines rather than a concession. It involves high-dose progestin treatment, usually delivered by a hormone-releasing intrauterine device, together with repeat biopsies every few months to confirm the atypia is regressing. Before starting, the diagnosis is confirmed carefully — slides reviewed, imaging to exclude a cancer invading the muscle wall — because the route is only safe if there is genuinely no carcinoma present. It also comes with two commitments: strict attendance for surveillance sampling, and an agreement to revert to surgery if the lining does not clear in a defined window. Referral to fertility services is usually made early.
How likely is atypical hyperplasia to turn into cancer?
Substantially more likely than ordinary hyperplasia, and still not inevitable. Long-term follow-up studies put progression at roughly a quarter to a third of women over about two decades if the condition is left untreated, compared with under 5 in 100 over 20 years for hyperplasia without atypia. Those are figures for groups of women, not predictions for an individual, and they describe untreated disease — the whole point of treating atypical hyperplasia is that the trajectory can be interrupted. If the uterus is removed, the risk of progression is removed with it. If hormone treatment is used and the lining clears on repeat biopsy, the risk falls sharply, though follow-up continues.
What causes atypical hyperplasia in the first place?
The same thing that causes hyperplasia generally: oestrogen acting on the uterine lining over a long period without enough progesterone to balance it. The commonest sources are excess body weight, because fat tissue produces oestrogen of its own; cycles in which no egg is released, so no progesterone follows, which is the mechanism in polycystic ovary syndrome and in irregular perimenopausal cycles; and oestrogen given as hormone replacement without a progesterone component in a woman who still has her uterus. Diabetes and insulin resistance add to it. Lynch syndrome is a separate, inherited cause worth considering when the diagnosis appears at a younger age than expected.
Medical disclaimer: This page explains a biopsy finding and is reviewed by a CION oncologist. It describes how atypical endometrial hyperplasia is classified and managed in general terms, following the World Health Organization classification and current NCCN, RCOG/BSGE and ESMO guidance. It is not an interpretation of your individual report, and the figures quoted describe groups of women rather than predicting what will happen to any one of them. Decisions about hysterectomy and about fertility-sparing treatment should be made with a specialist who has seen your pathology.